Analysis of information sources in references of the Wikipedia article "Bùng phát bệnh đậu mùa khỉ 2022-2023" in Vietnamese language version.
<ref> không hợp lệ: tên “aus” được định rõ nhiều lần, mỗi lần có nội dung khác<ref> không hợp lệ: tên “alarabiya” được định rõ nhiều lần, mỗi lần có nội dung khácBavarian Nordic, the biotech company that makes the vaccine, has announced a $119 million order placed by the U.S., with an option to buy $180 million more, for delivery in 2023 and 2024. Should the second option be exercised, it would work out to approximately 13 million doses.
Do environmental conditions in the UK support the natural reservoirs or vectors of disease? Outcome: yes. Quality of evidence: satisfactory. Various animal species have been identified as susceptible to MPXV. Rodents are considered natural reservoirs of infection, including rope squirrels, tree squirrels, Gambian pouched rats, dormice, non-human primates (21) and other species (22).[...]
<ref> không hợp lệ: tên “1stisrael” được định rõ nhiều lần, mỗi lần có nội dung khácThe panel warned that hedgehogs, rats, mice, squirrels, rabbits and hares could all harbour the virus if monkeypox was to spill into Britain's wildlife populations.
<ref> không hợp lệ: tên “alarabiya” được định rõ nhiều lần, mỗi lần có nội dung khác<ref> không hợp lệ: tên “1stisrael” được định rõ nhiều lần, mỗi lần có nội dung khác<ref> không hợp lệ: tên “aus” được định rõ nhiều lần, mỗi lần có nội dung khácThe panel warned that hedgehogs, rats, mice, squirrels, rabbits and hares could all harbour the virus if monkeypox was to spill into Britain's wildlife populations.
Do environmental conditions in the UK support the natural reservoirs or vectors of disease? Outcome: yes. Quality of evidence: satisfactory. Various animal species have been identified as susceptible to MPXV. Rodents are considered natural reservoirs of infection, including rope squirrels, tree squirrels, Gambian pouched rats, dormice, non-human primates (21) and other species (22).[...]
Bavarian Nordic, the biotech company that makes the vaccine, has announced a $119 million order placed by the U.S., with an option to buy $180 million more, for delivery in 2023 and 2024. Should the second option be exercised, it would work out to approximately 13 million doses.